RT @NatRevClinOncol: In phase Ib trial, the anti-PD-1 agent toripalimab resulted in a 20% ORR & a 35% DCR, with a mDoR of 15.2 mo in patien…
Phase 1b Study: Toripalimab in recurrent or metastatic neuroendocrine neoplasms. https://t.co/sOOMihLZ7x https://t.co/BvkAAkTycQ
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial https://t.co/oiHxMC0VVE
RT @nanudasmd: Exciting to see that results from this phase Ib study of toripalimab and the NET cohort of the SWOG 1609 study suggest a rol…
RT @nanudasmd: Exciting to see that results from this phase Ib study of toripalimab and the NET cohort of the SWOG 1609 study suggest a rol…
Exciting to see that results from this phase Ib study of toripalimab and the NET cohort of the SWOG 1609 study suggest a role for checkpoint inhibitors in poorly differentiated NEC @CCR_AACR @CureNETs @net_connectinfo https://t.co/PYhJTH62t3
RT @CellworksLife: Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms. https…
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms. https://t.co/7xzvFkrOYr
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial https://t.co/TTFzoPTam4
RT @CCR_AACR: OnlineFirst: Lu et al. show efficacy and safety of #antiPD1 antibody #Toripalimab as 2nd line treatment for patients with rec…
RT @NatRevClinOncol: In phase Ib trial, the anti-PD-1 agent toripalimab resulted in a 20% ORR & a 35% DCR, with a mDoR of 15.2 mo in patien…
OnlineFirst: Lu et al. show efficacy and safety of #antiPD1 antibody #Toripalimab as 2nd line treatment for patients with recurrent or metastatic #NeuroendocrineNeoplasms with high proliferation index. https://t.co/2fzRbiepOE https://t.co/WoGVm0PONR
RT @NatRevClinOncol: In phase Ib trial, the anti-PD-1 agent toripalimab resulted in a 20% ORR & a 35% DCR, with a mDoR of 15.2 mo in patien…
RT @NatRevClinOncol: In phase Ib trial, the anti-PD-1 agent toripalimab resulted in a 20% ORR & a 35% DCR, with a mDoR of 15.2 mo in patien…
In phase Ib trial, the anti-PD-1 agent toripalimab resulted in a 20% ORR & a 35% DCR, with a mDoR of 15.2 mo in patients with neuroendocrine neoplasms. PD-L1 >10%, a high TMB and ARID1A mutations were positively associated with a response: https://t
RT @CronaJoakim: Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms https://t…
@CCR_AACR | Efficacy, safety and #biomarkers of #toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial | Read Article: 🔎https://t.co/TTUL6Jtqg5 https://t.co/tFqHXoIXz2
RT @CronaJoakim: Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms https://t…
RT @CronaJoakim: Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms https://t…
Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms https://t.co/CLHn0sFFiq
Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial. https://t.co/dUEPb8R2IM
New article: Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial. https://t.co/goiDzHgoUf #melanoma #oncology
Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial https://t.co/4y2tnaVFH3